(GSK) |
| 0 (0%) 01-14 04:04 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 60.11 |
| Resistance 1: | 51.46 |
| Pivot price: | 49.58 |
| Support 1: | 48.83 |
| Support 2: | 47.20 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 3.580 |
| Book Value | 5.400 |
| PEG Ratio | 0.00 |
| Gross Profit | 11.535 |
| Profit Margin (%) | 17.08 |
| Operating Margin (%) | 32.61 |
| Return on Assets (ttm) | 7.1 |
| Return on Equity (ttm) | 41.5 |
Company news
Tue, 13 Jan 2026
JPM26: GSK banks on recent AI deals to offset patent expiries - Pharmaceutical Technology
Tue, 13 Jan 2026
GSK Executives Reinvest Dividends into Company Shares via Reward Plan - TipRanks
Mon, 12 Jan 2026
GSK Still Has Room To Run Despite Vaccine Cyclicality (NYSE:GSK) - Seeking Alpha
Mon, 12 Jan 2026
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) - BioSpace
Mon, 12 Jan 2026
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) - Business Wire
Thu, 08 Jan 2026
GSK inks a model deal in $50M bet on Noetik's cancer AI platform - Fierce Biotech
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
